학술논문
SARS-CoV-2 infection, inflammation and birth outcomes in a prospective NYC pregnancy cohort.
Document Type
Academic Journal
Author
Gigase FAJ; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY, USA; Department of Child and Adolescent Psychiatry, Erasmus Medical Center, Rotterdam, the Netherlands. Electronic address: f.gigase@erasmusmc.nl.; Jessel RH; Department of Obstetrics, Gynecology and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York City, NY, USA; Blavatnik Family Women's Health Research Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.; Kaplowitz E; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.; Boychuk N; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.; Ohrn S; Department of Obstetrics, Gynecology and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.; Ibroci E 1st; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.; Castro J; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.; Lynch J; Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.; Tubassum R; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.; Balbierz A; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.; Molenaar NM; Department of Psychiatry, Erasmus Medical Center, Rotterdam, the Netherlands.; Graziani M; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.; Missall R; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.; Flores T; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.; Stern T; Department of Obstetrics, Gynecology and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.; Carreno JM; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Krammer F; Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York City, NY, USA; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Adler A; Department of Obstetrics, Gynecology and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.; Brody RI; Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.; Lesseur C; Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.; Chen J; Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.; Ellington S; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.; Galang RR; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.; Snead MC; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.; Howell E; Department of Obstetrics, Gynecology and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York City, NY, USA; Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Stone J; Department of Obstetrics, Gynecology and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.; Bergink V; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY, USA; Department of Obstetrics, Gynecology and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York City, NY, USA; Blavatnik Family Women's Health Research Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.; Dolan S; Department of Obstetrics, Gynecology and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.; Lieb W; Department of Obstetrics, Gynecology and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York City, NY, USA; Blavatnik Family Women's Health Research Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA; Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.; Rommel AS; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.; de Witte LD; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.; Janevic T; Department of Obstetrics, Gynecology and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York City, NY, USA; Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
Source
Publisher: Elsevier/North-Holland Biomedical Press Country of Publication: Ireland NLM ID: 8001906 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7603 (Electronic) Linking ISSN: 01650378 NLM ISO Abbreviation: J Reprod Immunol Subsets: MEDLINE
Subject
Language
English
Abstract
Associations between antenatal SARS-CoV-2 infection and pregnancy outcomes have been conflicting and the role of the immune system is currently unclear. This prospective cohort study investigated the interaction of antenatal SARS-CoV-2 infection, changes in cytokine and HS-CRP levels, birthweight and gestational age at birth. 2352 pregnant participants from New York City (2020-2022) were included. Plasma levels of interleukin (IL)-1β, IL-6, IL-17A and high-sensitivity C-reactive protein (HS-CRP) were quantified in blood specimens obtained across pregnancy. Quantile and linear regression models were conducted to 1) assess the impact of antenatal SARS-CoV-2 infection, overall and by timing of detection of SARS-CoV-2 positivity (< 20 weeks versus ≥ 20 weeks), on birthweight and gestational age at delivery; 2) examine the relationship between SARS-CoV-2 infection and maternal immune changes during pregnancy. All models were adjusted for maternal demographic and obstetric factors and pandemic timing. Birthweight models were additionally adjusted for gestational age at delivery and fetal sex. Immune marker models were also adjusted for gestational age at specimen collection and multiplex assay batch. 371 (15.8%) participants were infected with SARS-CoV-2 during pregnancy, of which 98 (26.4%) were infected at < 20 weeks gestation. Neither SARS-CoV-2 infection in general nor in early or late pregnancy was associated with lower birthweight nor earlier gestational age at delivery. Further, we did not observe cytokine or HS-CRP changes in response to SARS-CoV-2 infection and thus found no evidence to support a potential association between immune dysregulation and the diversity in pregnancy outcomes following infection.
Competing Interests: Declaration of Competing Interest The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer (before 2020), and is currently consulting for Pfizer, Seqirus, 3rd Rock Ventures and Avimex and he is a co-founder and scientific advisory board member of CastleVax. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2. The other authors have nothing to report. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
(Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
Competing Interests: Declaration of Competing Interest The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer (before 2020), and is currently consulting for Pfizer, Seqirus, 3rd Rock Ventures and Avimex and he is a co-founder and scientific advisory board member of CastleVax. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2. The other authors have nothing to report. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
(Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)